The state of Bayer’s late-stage pipeline is a cause for concern at a time when Xarelto revenues are getting battered by generic competition. Nonetheless CEO Bill Anderson has told Scrip that the troubled German firm is not going to spend big on bringing in late-stage assets that could ease its patent cliff woes.
Bayer Will Not Take Risky Bets To Close Xarelto Revenue Gap
The German major’s CEO Bill Anderson will not be tempted to go out and make a big bid on a late-stage asset to fill the revenue gap caused by Xarelto’s patent expiries, telling Scrip that " in the pharma business, that's pretty much worse than going to the casino.”
